
Tenpoint Therapeutics launches with $70M to restore vision with stem cell therapies and ‘reprogramming’ medicines
Although numerous biotech companies are developing gene therapies to correct eyesight, these approaches largely require the affected cells to remain intact — while many forms of vision loss are caused by dead or dying cells. That’s why a new startup is betting that advances in stem cell biology will enable treatments that restore vision by replacing or regenerating vital tissues lost to disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.